Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
May 08, 2024 16:05 ET
|
Design Therapeutics, Inc.
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study...
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024 06:30 ET
|
Design Therapeutics, Inc.
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced...
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
March 19, 2024 16:01 ET
|
Design Therapeutics, Inc.
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025...
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
March 12, 2024 06:30 ET
|
Design Therapeutics, Inc.
CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today...
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
November 13, 2023 16:05 ET
|
Design Therapeutics, Inc.
Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 ...
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
August 14, 2023 16:05 ET
|
Design Therapeutics, Inc.
Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Showed Significant Increase in FXN mRNA Levels in Skeletal Muscle Company Expects to Resume a Multiple Dose...
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
August 14, 2023 16:01 ET
|
Design Therapeutics, Inc.
DT-216 Resulted in a Significant Increase in FXN mRNA Levels in Skeletal Muscle of FA Patients Treatment Generally Well-Tolerated; Injection Site Reactions Attributable to Current Formulation...
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
May 31, 2023 06:30 ET
|
Design Therapeutics, Inc.
CARLSBAD, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,...
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
May 09, 2023 16:05 ET
|
Design Therapeutics, Inc.
Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Expected in the Third Quarter of 2023 Progress Across GeneTAC™ Small Molecule Pipeline with IND Submissions...
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
April 24, 2023 06:30 ET
|
Design Therapeutics, Inc.
Treatment with DT-168 Eye Drops Reduced Nuclear Foci and Significantly Improved Mis-Splicing In Vitro Company On-track to Submit Investigational New Drug Application for DT-168 in the Second Half of...